Common checkpoint inhibitors include drugs like pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy). Pembrolizumab and nivolumab are PD-1 inhibitors, while ipilimumab targets CTLA-4. These drugs have been approved for the treatment of various cancers, including melanoma, lung cancer, and renal cell carcinoma.
